Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK’s RSV Vaccine Prospects In Youngest Pediatric Patients Looks Unlikely Per US FDA Label

Executive Summary

Arexvy is the first vaccine approved for the respiratory virus, but GSK's RSV program may lose out on a key population due to safety concerns for individuals younger than two. For Arexvy, CDC’s advisory committee could limit recommendation to 65 and up at June meeting.

You may also be interested in...



Pfizer’s Abrysvo Is First Maternal Vaccine For RSV To Protect Infants

The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.

GSK Seeks To Prevent Pfizer From Selling Its Rival RSV Vaccine In the US

Claiming Pfizer’s Abrysvo infringes four of its patents, GSK asks court to permanently enjoin Pfizer from making or selling the vaccine in the US but would exempt the pending maternal indication.

AstraZeneca’s RSV Antibody May Need More Data Due To Impact Of Maternal Vaccines

Maternal vaccines may cause first RSV infections to occur when infants are older, requiring increased study of disease patterns and additional dosing data on AstraZeneca/Sanofi’s nirsevimab in older babies. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel